Immuneering IMRX
NASDAQ IMRX
$4.07 +0.04 (+0.99%)
At close: Oct 2, 2026 · 4:00 PM EDT

Immuneering (IMRX) Gains from Sales and Divestitures (2022 - 2025)

Updated

Immuneering's Gains from Sales and Divestitures was -$2,093 in Q4 2025, compared with -$5,469 a year earlier.

Analysis

Immuneering (IMRX) Gains from Sales and Divestitures (2022 - 2025) Analysis & Trends

From Q4 2022 onward, Immuneering has reported Gains from Sales and Divestitures for 7 quarters.

  • In earlier years, Gains from Sales and Divestitures was -$6,784 in FY2024, -$3,939 in FY2023 and -$5,170 in FY2022.
  • The Q4 2025 figure marks the highest quarterly Gains from Sales and Divestitures since Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Immuneering 263.32 Mn 263.32 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -2,093.00
Dec 31, 2024 -5,469.00
Sep 30, 2024 -1,315.00
Dec 31, 2023 -2,456.00
Jun 30, 2023 -817.00
Mar 31, 2023 -666.00
Dec 31, 2022 -5,170.00
API Access

Immuneering Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=IMRX&period=max&api_key=YOUR_API_KEY